Residents of 23 U.S. states can buy medical marijuana to treat everything from cancer pain to anxiety, but U.S. scientists must wade through onerous paperwork to score the drug for study. Their sole dealer is the National Institute on Drug Abuse (NIDA), which has a contract with the University of Mississippi in Oxford to produce marijuana for research purposes.
The agency has long faced complaints that its marijuana is too weak to represent what is sold on the street, and contains low levels of the non-psychedelic chemicals that show therapeutic promise for conditions such as epilepsy and chronic pain. Now, with legal marijuana increasingly available to the U.S. public, NIDA is quietly changing course — working to expand the amount and variety of the drug available for study.
“We want to be able to evaluate the claims that marijuana is therapeutically beneficial” and to explore treatments for addiction, says Nora Volkow, director of NIDA in Rockville, Maryland. [Read more from the weekly science journal Nature]
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Notify me of follow-up comments by email.
Notify me of new posts by email.
With less than a month left in Ohio’s legislative session, a bill that would legalize recreational marijuana use will need to move quickly to become law. House Bill 382, introduced…
Backers sought to ease path to passage before end of year. Some Republicans rejected adding extras on defense legislation A marijuana banking measure was left out of a must-pass defense bill,…
PRESS RELEASE Jointly Matches Empowers Budtenders with Goal-Specific Product Insights Jointly, the cannabis discovery company, today announced the launch of Jointly Matches, a first-of-its-kind, goal-based, data-driven cannabis shopping cart builder for…
Although the cannabis industry’s pace can cause time to fly by in dog years, Kyla Sirni, the co-founder and CEO of Dispense, a cannabis eCommerce platform launched in 2020, is…